title: In vitro steroidogenic effects of neuropeptide Y (NPY1-36), Y1 and Y2 receptor agonists (Leu31-Pro34 NPY, NPY18-36) and peptide YY (PYY) on rat adrenal capsule/zona glomerulosa.
abstract: The effects of neuropeptide Y (NPY1-36), of two analogs (Leu31-Pro34 NPY and NPY18-36) and of Peptide YY (PYY) on aldosterone and corticosterone secretions by freshly isolated rat adrenal capsule/zona glomerulosa preparations were investigated in vitro. NPY-related peptides (NPY1-36, Leu31-Pro34 NPY, NPY18-36), but not PYY, induced a dose-dependent release of aldosterone at concentrations ranging from 10(-8) to 10(-6) M. All the investigated peptides failed to significantly affect corticosterone secretion in concentrations ranging from 10(-10) to 10(-6) M (NPY1-36, NPY18-36), 10(-11) to 10(-6) M (Leu31-Pro34 NPY) or 10(-9) to 10(-6) M (PYY). Aldosterone secretion by this preparation of isolated adrenal capsule/zona glomerulosa was also significantly stimulated by high potassium levels (55 mEq) or by angiotensin II (AII) in concentrations ranging from 10(-8) to 10(-6) M. Moreover, NPY and Y1 or Y2 receptor agonists were positive aldosterone releasing agents as potent as AII. The present data support the existence of: (1) NPY binding sites of the Y3-like subtype, on rat adrenal capsule/zona glomerulosa. (2) A stimulatory effect of NPY on aldosterone production. So that the NPYergic innervation of the rat adrenal capsule/zona glomerulosa could be implicated in the multifactorial control of aldosterone production.
authors: Laboratoire de Neuroendocrinologie du Développement, Université de Lille 1, Villeneuve d'Ascq, France.
authors: F
authors: F
authors: Bernet
authors: E
authors: E
authors: Maubert
authors: J
authors: J
authors: Bernard
authors: V
authors: V
authors: Montel
authors: J P
authors: JP
authors: Dupouy
mesh_terms: D000450:Aldosterone / Q000096:biosynthesis* / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D003345:Corticosterone / Q000096:biosynthesis* / Q000378:metabolism; D008297:Male; D009478:Neuropeptide Y / Q000031:analogs & derivatives / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010446:Peptide Fragments; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology*; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015384:Zona Glomerulosa / Q000187:drug effects* / Q000378:metabolism
chemical_list: D009478:Neuropeptide Y; D010446:Peptide Fragments; D010455:Peptides; D019894:Peptide YY; D000804:Angiotensin II; C059889:neuropeptide Y (18-36); C062259:neuropeptide Y, Leu(31)-Pro(34)-; D000450:Aldosterone; D011188:Potassium; D003345:Corticosterone